Patients with the TT genotype may have decreased likelihood of achieving a proton pump inhibitor-responsive esophageal eosinophilia outcome following esomeprazole therapy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence response to esomeprazole.